Core Viewpoint - Kamada Ltd. reported record revenue and profitability for the full year 2025 and declared a cash dividend of $0.25 per share, totaling approximately $14.4 million, to be paid on April 6, 2026 [1][2][3] Financial Performance - The company announced strong financial results for 2025, which supported the decision to distribute a cash dividend [3] - The cash dividend represents at least 50% of the company's annual net income, as per the newly adopted annual cash dividend policy [2] Dividend Policy - The Board of Directors has adopted a policy to distribute an annual dividend of at least 50% of net income, subject to discretion and legal requirements [2] - The dividend payment will be subject to tax withholding in accordance with Israeli tax law [3] Company Overview - Kamada Ltd. is a global biopharmaceutical company focused on rare and serious conditions, with a portfolio of specialty plasma-derived products [4] - The company is controlled by FIMI Opportunity Funds, which owns approximately 38% of the outstanding shares [4] Growth Strategy - Kamada's growth strategy includes organic growth of its commercial portfolio, distribution of third-party pharmaceutical products, ramping up plasma collection operations, and pursuing mergers and acquisitions [4] - The company aims to enhance its marketed products portfolio and leverage its financial strength for long-term growth [4]